Abstract Library

#2061 Midgut Carcinoids Presenting as Subacute Intestinal Obstruction. A Case Report of Territory Care Hospital.

Introduction: Midgut carcinoids are well differentiated neuroendocrine tumors possessing secretary properties releasing various peptides. Over the past few decades, there incidence has been increased. Since countries like Pakistan lack the diagnostic facilities, they are often misdiagnosed.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Fatima A

Authors: Fatima A, Zaidi S,

Keywords: midgut carcinoid, liver metastasis, misdiagnosis, surgery,

#2038 Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study: 177Lu-Dotatate vs. High Dose Octreotide in Progressive Midgut Neuroendocrine Tumors

Introduction: The NETTER-1 final per-protocol statistical analysis (cut–off date 24.07.2015) of PFS, the primary endpoint of the study, showed a significant difference (p<0.0001) between the treatment arms.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Jonathan S

Authors: Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D,

Keywords: 177Lu-DOTATATE, PRRT, NET, Quality of Life,

#1714 CALM-NET, A Multicentre, Exploratory Study to Assess the Clinical Value of Circulating Tumour Cells (CTCs) Enumeration in Patients (Pts) with Functioning Midgut NETs Receiving Lanreotide Autogel (LAN)

Introduction: The presence of CTCs confers adverse prognosis in metastatic NET pts with heterogenous treatment history. Post treatment CTC count correlates with disease progression and overall survival.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Meyer T

Authors: Meyer T, Higgs K, Hickling M, Houchard A,

Keywords: midgut neuroendocrine tumor, CTC, lanreotide,

#1676 NETTER-1 Phase III Trial: Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors

Introduction: Impairment in quality of life caused by tumor load and hormone-related symptoms is frequent in GEP-NET patients. In the Phase III NETTER-1 trial, patients with advanced, progressive midgut NETs were randomized to treatment with 177Lu-DOTATATE (177Lu; Lutathera®) or high-dose (60 mg) Octreotide LAR (Oct).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D,

Keywords: 177Lu-DOTATATE, PRRT, NET, Quality of Life,

#1602 Systematic Review of Resecting Primary Tumor in MNETs Patients with Unresectable Liver Metastases

Introduction: Treatment for midgut neuroendocrine tumors (MNETS) with unresectable liver metastasis has long been a controversial issue.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Zhao H

Authors: Guo J, Bi X, Zhou J, Li Z, Huang Z,

Keywords: midgut neuroendocrine tumor, liver metastasis, primary tumor resection,